Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
PTC Therapeutics (PTCT) Stock Price & Analysis
302 Followers
PTCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$17.53 - $59.84
Previous Close$31.7
Volume172.28K
Average Volume (3M)887.14K
Market Cap
$2.40B
Enterprise Value$2.84B
Total Cash (Recent Filing)$294.81M
Total Debt (Recent Filing)$704.35M
Price to Earnings (P/E)-4.1
Beta1.01
Next Earnings
Aug 01, 2024EPS Estimate
-$1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.68
Shares Outstanding76,696,785
10 Day Avg. Volume832,102
30 Day Avg. Volume887,141
Standard Deviation0.14
R-Squared0.06
Alpha0.00114
Financial Highlights & Ratios
Price to Book (P/B)-1.93
Price to Sales (P/S)14.52
Price to Cash Flow (P/CF)-6.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.74
Enterprise Value/Gross Profit4.07
Enterprise Value/Ebitda-8.05
Forecast
1Y Price Target
$29.30Price Target Upside-6.34% Downside
Rating ConsensusHold
Number of Analyst Covering11
PTC Therapeutics News
PremiumCompany Announcements
PTC Therapeutics Q1 Financial Results Conference Call
Bulls Say, Bears Say
Bulls Say
Drug Approval And Revenue ProjectionEvrysdi has been approved in most major markets, with expected global traction and projected revenues of $3B by 2028 for PTC.
Financial PerformanceTotal revenue for Q1 came in at $210 million, significantly above consensus estimates, largely due to better than expected sales of Translarna and Emflaza.
Pipeline DevelopmentNew Drug Applications for multiple treatments are planned for submission, indicating progress in the company's pipeline.
Bears Say
Financial OutlookFull year 2024 guidance unchanged despite the beat in 1Q24, leading to questions about the sustainability of the sales trend.
Market CompetitionEmflaza is likely to face pressure from generics and new competitive agents starting in 2024.
Regulatory ChallengesTranslarna approval in the U.S. is viewed as unlikely due to its regulatory history.
---
Ownership Overview
20.73% Insiders
41.07% Mutual Funds
26.70% Other Institutional Investors
11.50% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $17.53 and its highest was $59.84 in the past 12 months.
What is PTC Therapeutics’s market cap?
Currently, no data Available
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 79 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on Apr 25, 2024. The company reported -$1.2 earnings per share for the quarter, beating the consensus estimate of -$1.275 by $0.075.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Overvalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is -$1.26.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 76,696,785 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of -$1.2 in its last earnings report, beating expectations of -$1.275. Following the earnings report the stock price went up 12.083%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Among the largest hedge funds holding PTC Therapeutics’s share is Blackstone Inc.. It holds PTC Therapeutics’s shares valued at 30M.
---
PTC Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$29.30 (-6.34% Downside)
$29.30 (-6.34% Downside)
Blogger Sentiment
Bullish
PTCT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 239.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $156.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 10.2%
Last 30 Days ▼ 10.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-42.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.24%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
---
PTCT Earnings Call
Q1 2024
0:00 / 0:00
---
PTCT Stock 12 Month Forecast
Average Price Target
$29.30
▼(-6.34% Downside)
Technical Analysis
Sarepta Therapeutics
―
Ultragenyx Pharmaceutical
―
Crispr Therapeutics AG
―
Bluebird Bio
―
Best Analysts Covering PTCT
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+12.19%
reiterated a sell rating 19 days ago
Copying Paul Choi's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +12.19% per trade.
---